A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

Table 4 Resource consumption and costs (€) of post-discharge VTE events after THR and TKR from the social health insurance perspective (costs in 2010 euros)

Resources		DVT² (units)	Non-fatal PE² (units)	Fatal PE³(units)	Unit prices(€)	Source
In hospital	Diagnosis, treatment and hospitalization (€)	1,838.33	3,543.48	1,256.43		[16]
Outpatient	Treatment
	Outpatient visit¹	1.0	1.0	0.0	53.16	[19, 27, 28, 30]
	Phenprocoumon (days)	83.4	79.7	0.0	0.17	[19, 27, 28, 30]
	INR measurement	10.0	10.0	0.0	1.68	[19, 27, 28, 30]
	Compression stockings	2.0	2.0	0.0	36.90	[19, 27, 28, 30]
Total costs for health insurance (€)		1,995.89	3,700.43	1,256.43

VTE = venous thromboembolism, THR = total hip replacement, TKR = total knee replacement, DVT = deep vein thrombosis, PE = pulmonary embolism.
¹Flat rate including all outpatient visits and blood samples every quarter (3 months).
²It was assumed that every post-discharge DVT and PE leads to hospital admission.
³In the case of a fatal PE, it was assumed that death would occur on the day of re-admission.

ISSN: 1472-6963